MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
TNXP - Tonix Pharmaceuticals Holding Corp
$1.25
0.03(2.46%)9:00:00 PM 2/24/2021
Tonix Pharmaceuticals is a pharmaceutical company based in New York City that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. The company's predecessors were Tamandare Explorations Inc. which had been formed in 2007 as a mining wildcat vehicle focused on land in Nevada and the shares of which were traded over the counter, and L & L Technologies, LLC, which had been formed in 1996 by Seth Lederman and Donald Landry to repurpose drugs for CNS development. L&L had formed Janus Pharmaceuticals, Inc., which later became Vela Pharmaceuticals, Inc. to develop some of its inventions, and Vela returned those assets to L&L in 2006. L&L placed them in a subsidiary called Krele Pharmaceuticals, Inc., and that subsidiary and Tamandare Explorations Inc. performed a reverse merger in October 2011; the new entity was renamed Tonix Pharmaceuticals Holding Corp. and Lederman was named CEO. It was listed on the NASDAQ exchange in 2013 under the symbol TNXP.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/11/2021TNXP
    Tonix Pharma Shares Rally After In-Licensing Of Technology For A Rare Genetic Eating Disorder

    Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has licensed technology using oxytocin-based therapeutics from the French National Institute of Health and Medical Research (Inserm) for the treatment of Prader-Willi syndrome, characterized by a constant sense of hunger (hyperphagia), which leads to severe obesity resulting in physical, mental and behavioral problems. The co-exclusive license allows Tonix to expand its intranasal potentiated oxytocin development program to a new indication, desi...

    02/11/2021TNXP
    Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)

    Expands Proprietary Uses of Tonix’s Potentiated Oxytocin for Intranasal Administration Disorder Stunts Growth of Newborns and, Paradoxically, Can Cause Excessive Hunger During Childhood and Beyond CHATHAM, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi ...

    02/10/2021TNXP
    Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference

    CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021. The Company’s presentation will be made through the BIO CEO & Investor Digital Conference website and available on demand to registered participant...

    02/9/2021TNXP
    Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

    CHATHAM, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of approximately $70.0 million before deducting fees and other estimated offering expenses. The Company sold 58,333,334 shares of common stock at $1.20 per share. A.G.P./Alliance Global Partners acted ...

    02/9/2021TNXP
    Why Tonix Pharmaceuticals Stock Surged Today

    What happened Shares of Tonix Pharmaceuticals (NASDAQ: TNXP) jumped 22% on Monday after the biopharmaceutical company said it would develop a COVID-19 skin test.  So what  Tonix intends to develop a diagnostic skin test, called TNX-2100, to measure T-cell immunity to SARS-CoV-2, the virus that causes COVID-19.

    02/8/2021TNXP
    Tonix Pharmaceuticals $70M; Plans To Develop COVID-19 Skin Test

    Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has entered into a securities purchase agreement with institutional investors to purchase 58.3 million shares at $1.20 per share, raising gross proceeds of approximately $70 million. The offering is expected to close by February 9. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. Earlier today, Tonix received a written response from the FDA to a Type B pre-investigational new drug meeting package describing ...

    02/8/2021TNXP
    Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

    CHATHAM, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 58,333,334 shares of common stock, par value $0.001 per share at an offering price of $1.20 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proce...

    02/8/2021TNXP
    Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity

    Pre-IND Meeting Written Response from FDA Provides Guidance on Product Development and Clinical Testing Protocol Intradermal Test is Designed to Measure SARS-CoV-2 Specific Delayed Type Hypersensitivity (DTH), the Classic Method of Measuring T Cell Immunity to Tuberculosis and Other Pathogens Multiple Potential Uses Include Functional Measure of T Cell Immunity to SARS-CoV-2; Aid to COVID-19 Diagnosis and Public Health Surveillance; Endpoint for COVID-19 Vaccine Trials CHATHAM, N.J., Feb. 08, 20...